<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04787965</url>
  </required_header>
  <id_info>
    <org_study_id>NBI-OPC-PD4006</org_study_id>
    <nct_id>NCT04787965</nct_id>
  </id_info>
  <brief_title>Opicapone Treatment Initiation Open-Label Study</brief_title>
  <acronym>OPTI-ON</acronym>
  <official_title>Opicapone Treatment Initiation Open-Label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurocrine Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurocrine Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study to describe the treatment patterns and clinical outcomes&#xD;
      observed with use of ONGENTYS as adjunctive treatment to levodopa/carbidopa in Parkinson's&#xD;
      disease patients experiencing &quot;off&quot; episodes with motor fluctuations&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ONGENTYS treatment patterns</measure>
    <time_frame>6 months</time_frame>
    <description>Reason for initiating treatment and discontinuation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PD Status</measure>
    <time_frame>6 months</time_frame>
    <description>PD Status Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-C</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical Global Impression of Change Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MDS-UPDRS Parts I, II, and IV</measure>
    <time_frame>6 months</time_frame>
    <description>Movement Disorder Society-Unified Parkinson's Disease Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PDQ-8</measure>
    <time_frame>6 months</time_frame>
    <description>Parkinson's Disease Questionnaire-8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGI-C</measure>
    <time_frame>6 months</time_frame>
    <description>Patient Global Impression of Change Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NoMoFa</measure>
    <time_frame>6 months</time_frame>
    <description>Non-Motor Fluctuation Assessment</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>ONGENTYS</arm_group_label>
    <description>Opicapone 50 mg capsule once daily for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Opicapone</intervention_name>
    <description>Opicapone as adjunctive treatment to levodopa/carbidopa over a 6-month period</description>
    <arm_group_label>ONGENTYS</arm_group_label>
    <other_name>ONGENTYS</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Parkinson's disease patients experiencing &quot;off&quot; episodes with motor fluctuations, who are&#xD;
        currently being treated by a neurologist and require adjunctive treatment to&#xD;
        levodopa/carbidopa&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be able to complete electronic patient-reported outcome instruments&#xD;
&#xD;
          -  Parkinson's disease patients experiencing &quot;off&quot; episodes&#xD;
&#xD;
          -  Patient receiving concomitant levodopa/carbidopa, and as deemed appropriate by the&#xD;
             physician, newly initiating ONGENTYS as adjunctive treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is not cognitively able to complete the study requirements&#xD;
&#xD;
          -  Patient is not able to complete the study duration of 6 months&#xD;
&#xD;
          -  History of moderate or severe hepatic impairment&#xD;
&#xD;
          -  Patient has end-stage renal disease&#xD;
&#xD;
          -  Concomitant use of non-selective monoamine oxidase (MAO) inhibitor or&#xD;
             catechol-O-methyltransferase (COMT) inhibitors (patients entering study may switch&#xD;
             from other COMT inhibitors to ONGENTYS)&#xD;
&#xD;
          -  History of pheochromocytoma, paraganglioma, or other catecholamine-secreting neoplasms&#xD;
&#xD;
          -  Currently enrolled in an interventional clinical trial&#xD;
&#xD;
          -  Currently or previously received ONGENTYS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olga Klepitskaya, MD, FAAN</last_name>
    <role>Study Director</role>
    <affiliation>Neurocrine Biosciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cheryl Chen</last_name>
    <phone>858-617-7744</phone>
    <email>cechen@neurocrine.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neurocrine clinical site</name>
      <address>
        <city>Los Gatos</city>
        <state>California</state>
        <zip>95032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurocrine clinical site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurocrine clinical site</name>
      <address>
        <city>Christiansburg</city>
        <state>Virginia</state>
        <zip>24073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurocrine clinical site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurocrine clinical site</name>
      <address>
        <city>Auburn</city>
        <state>Washington</state>
        <zip>98002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurocrine clinical site</name>
      <address>
        <city>Crab Orchard</city>
        <state>West Virginia</state>
        <zip>25827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P; Bi-Park 1 investigators. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016 Feb;15(2):154-165. doi: 10.1016/S1474-4422(15)00336-1. Epub 2015 Dec 23.</citation>
    <PMID>26725544</PMID>
  </reference>
  <reference>
    <citation>Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha JF, McCrory M, Soares-da-Silva P; BIPARK-2 Study Investigators. Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol. 2017 Feb 1;74(2):197-206. doi: 10.1001/jamaneurol.2016.4703.</citation>
    <PMID>28027332</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2021</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's disease (PD)</keyword>
  <keyword>Levodopa</keyword>
  <keyword>Carbidopa</keyword>
  <keyword>Motor Fluctuations</keyword>
  <keyword>Non-Motor Fluctuations</keyword>
  <keyword>Adjunctive treatment</keyword>
  <keyword>COMT inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opicapone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

